Relative bioavailability of coenzyme Q10 formulations in human subjects

International Journal for Vitamin and Nutrition Research

Volumn 68, Issue 2, 1998, Pages 109-113

  Chopra, Raj K ^a   Goldman, Robert ^b   Sinatra, Stephen T ^c   Bhagavan, Hemmi N ^d  

^a Tishcon Corporation   (United States)

^b Biosytes (USA)   (United States)

^c New England Heart Center   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Absorption; Bioavailability; Capsules; Coenzyme Q 10; Dosage forms; Humans; Softgels; Tablets; Ubiquinone 50

Indexed keywords

DRUG DERIVATIVE; UBIDECARENONE; UBIQUINONE;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD; GEL; HUMAN; KINETICS; MIDDLE AGED; SOLUBILITY;

ADULT; BIOLOGICAL AVAILABILITY; GELS; HUMANS; KINETICS; MIDDLE AGED; SOLUBILITY; UBIQUINONE;

EID: 0031980442     PISSN: 03009831     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Biomedical and Clinical Aspects of Coenzyme Q (Folkers, K., Yamagami, T. and Littarry, G.P., Eds.), Vol. 6 (1991), Elsevier, Amsterdam.
2. Kamikawa, T., Kobayashi, A., Yamashita, T., Hayashi, H. and Yamazaki, N. (1985) Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am. J. Cardiol. 56, 247-251.
3. Lockwood, K., Moesgaard, S., Yamamoto, T. and Folkers, K. (1995) Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem. Biophys. Res. Commun. 212, 172-177.
4. Weis, M., Mortensen, S.A., Rassing, M.R., Moller-Sonnergaard, J., Poulsen, G. and Rasmussen, S.N. (1994) Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol. Aspects Med. 15, s273-s280.
5. Folkers, K., Moesgaard, S. and Morita, M. (1994) A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol. Aspects Med. 15, s281-s285.
6. Kaikkonen, J., Nyyssonen, K., Porkkala-Sarataho, E., Poulsen, H.E., Metsa-Ketela, T., Hayn, M., Salonen, R. and Salonen, J.T. (1997) Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL + LDL fraction: Absorption and antioxidative properties of oil and granule-based preparations. Free Rad. Biol. Med. 22, 1195-1202.
7. Chopra, R., Goldman, R. and Bhagavan, H.N. (1997) A new coenzyme QlO preparation with enhanced bioavailability. FASEB J. 11, A586.
8. The United States Pharmacopeia/The National Formulary (1995) Disintegration and dissolution of nutritional supplements, pp. 2184-2185. The United States Pharmacopeial Convention, Inc., Rockville, MD (USA).
9. Okamoto, T., Fukunaga, Y., Ida, Y. and Kishi, T. (1988). Determination of reduced and total ubiquinones in biological materials by liquid chromatography with electrochemical detection. J. Chromat. 342, 35-46.
10. STATA: Reference Manual (1996) Release #4, Computing Resource Center, Los Angeles, CA.
11. Porter, D.A., Costill, D.L., Zackwieja, J.J., Krzeminski, K., Fink, W.J., Wagner, E. and Folkers, K. (1995) The effect of oral coenzyme Q10 on the exercise tolerance of middle-aged, untrained men. Int. J. Sports Med. 16, 421-427.
12. Langsjoen, P.H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T. and Langsjoen, P.H. (1988) Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin. Wochenschr. 66, 583-590.
13. Langsjoen, P.H., Langsjoen, P. and Folkers, K. (1989) Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol. 65, 521-523.
14. Laaksonen, R., Fogelholm, M., Himberg, J.-J., Laakso, J. and Salorinne, Y. (1995) Ubiquinone supplementation and exercise capacity in trained young and older men. Europ. J. Appl. Physiol. 72, 95-100.
15. Lonnrot, K., Metsa-Ketela, T., Molnar, G., Ahonen, J.-P., Latvala, M., Peltola, J., Pietila, T. and Alho, H. (1996) The effect of ascorbate and ubiquinoe supplementation on plasma and CSF total antioxidant capacity. Free Rad. Biol. Med. 21, 211-217.